Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) EBT: 2010-2025

Historic EBT for Catalyst Pharmaceuticals (CPRX) over the last 15 years, with Sep 2025 value amounting to $71.0 million.

  • Catalyst Pharmaceuticals' EBT rose 24.18% to $71.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $285.8 million, marking a year-over-year increase of 51.38%. This contributed to the annual value of $216.3 million for FY2024, which is 128.82% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its EBT stood at $71.0 million for Q3 2025, which was up 2.51% from $69.3 million recorded in Q2 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' EBT peaked at $74.2 million during Q4 2024, and registered a low of -$38.0 million during Q3 2023.
  • In the last 3 years, Catalyst Pharmaceuticals' EBT had a median value of $55.8 million in 2024 and averaged $47.5 million.
  • In the last 5 years, Catalyst Pharmaceuticals' EBT slumped by 246.20% in 2023 and then surged by 250.46% in 2024.
  • Quarterly analysis of 5 years shows Catalyst Pharmaceuticals' EBT stood at $12.8 million in 2021, then surged by 157.61% to $33.0 million in 2022, then skyrocketed by 41.50% to $46.7 million in 2023, then soared by 58.82% to $74.2 million in 2024, then rose by 24.18% to $71.0 million in 2025.
  • Its EBT was $71.0 million in Q3 2025, compared to $69.3 million in Q2 2025 and $71.3 million in Q1 2025.